You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
AstraZeneca
Boehringer Ingelheim
Dow
Express Scripts

Last Updated: February 16, 2020

DrugPatentWatch Database Preview

Alvogen Company Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Alvogen

Drugs and US Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alvogen THYRO-TABS levothyroxine sodium TABLET;ORAL 021116-012 Dec 7, 2004 AB2,AB4 RX Yes No   Start Trial   Start Trial
Alvogen TENORETIC 50 atenolol; chlorthalidone TABLET;ORAL 018760-002 Jun 8, 1984 AB RX Yes No   Start Trial   Start Trial
Alvogen Pine Brook METHYLPHENIDATE HYDROCHLORIDE methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 210818-002 Nov 30, 2018 AB RX No No   Start Trial   Start Trial
Alvogen ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-002 Apr 21, 1993 AB1 RX Yes Yes   Start Trial   Start Trial
Alvogen Pine Brook HYDROCODONE BITARTRATE AND ACETAMINOPHEN acetaminophen; hydrocodone bitartrate TABLET;ORAL 209958-001 Oct 24, 2018 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen SPECTAZOLE econazole nitrate CREAM;TOPICAL 018751-001 Dec 23, 1982 3,839,574   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982 3,836,671   Start Trial
Alvogen TENORETIC 50 atenolol; chlorthalidone TABLET;ORAL 018760-002 Jun 8, 1984 3,934,032   Start Trial
Alvogen NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-002 Jan 5, 1996 5,637,320   Start Trial
Alvogen NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-001 Jan 5, 1996 5,637,320   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ALVOGEN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 450 mg ➤ Subscribe 2013-02-28

Supplementary Protection Certificates for Alvogen Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1499331 13C0055 France   Start Trial PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
1304992 CR 2013 00053 Denmark   Start Trial PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
2203431 CR 2015 00014 Denmark   Start Trial PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0268956 SPC/GB98/040 United Kingdom   Start Trial PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
1429780 SPC/GB12/058 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Express Scripts
Merck
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.